Zulian Francesco, Balzarin Marta, Birolo Carolina
a Pediatric Rheumatology Unit, Department for Woman and Child Health , University of Padua , Padua , Italy.
Expert Rev Clin Immunol. 2017 Apr;13(4):361-369. doi: 10.1080/1744666X.2017.1243467. Epub 2016 Oct 11.
Juvenile Systemic Sclerosis (JSSc) is one of the most severe multi-systemic connective tissue conditions encountered in pediatric rheumatology. Due to its high morbidity and mortality rate, early diagnosis, proper assessment and effective treatment are crucial. Areas covered: In this review, we will focus on the recent advances on the classification and general management of JSSc based on the literature search and on the Authors' experience. Expert commentary: Classification criteria for the pediatric forms of systemic sclerosis, the new proposed assessment tools, such as the juvenile systemic sclerosis severity score, named J4S, and new techniques for the internal organs assessment, will facilitate both daily practice and research projects. Unfortunately, no known drugs seem to be effective in preventing the development of disease complications although a few treatments, undertaken according to experience in adults, have shown some effects in arresting the disease progression.
青少年系统性硬化症(JSSc)是儿科风湿病中最严重的多系统结缔组织疾病之一。由于其高发病率和死亡率,早期诊断、恰当评估和有效治疗至关重要。涵盖领域:在本综述中,我们将基于文献检索和作者经验,重点关注JSSc分类和综合管理方面的最新进展。专家评论:儿童系统性硬化症的分类标准、新提出的评估工具,如青少年系统性硬化症严重程度评分(称为J4S)以及内脏评估的新技术,将有助于日常实践和研究项目。遗憾的是,尽管根据成人经验进行的一些治疗在阻止疾病进展方面显示出一定效果,但尚无已知药物似乎能有效预防疾病并发症的发生。